US4693966A - Human monoclonal antibodies from lymphocytes of patients with malignant melanoma - Google Patents

Human monoclonal antibodies from lymphocytes of patients with malignant melanoma Download PDF

Info

Publication number
US4693966A
US4693966A US06/474,618 US47461883A US4693966A US 4693966 A US4693966 A US 4693966A US 47461883 A US47461883 A US 47461883A US 4693966 A US4693966 A US 4693966A
Authority
US
United States
Prior art keywords
human
cells
cell
antigens
monoclonal antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US06/474,618
Inventor
Alan N. Houghton
Hannah Brooks
Richard J. Cote
Herbert F. Oettgen
Lloyd J. Old
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Priority to US06/474,618 priority Critical patent/US4693966A/en
Assigned to SLOAN-KETTERING INSTITUTE, A CORP. OF NEW YORK CITY reassignment SLOAN-KETTERING INSTITUTE, A CORP. OF NEW YORK CITY ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: BROOKS, HANNAH, COTE, RICHARD J., HOUGHTON, ALAN N., OETTGEN, HERBERT F., OLD, LLOYD J.
Priority to EP84102522A priority patent/EP0118893A3/en
Priority to CA000449203A priority patent/CA1242158A/en
Priority to JP59046964A priority patent/JPS6012973A/en
Assigned to SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH reassignment SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: SLOAN-KETTING INSTITUTE
Application granted granted Critical
Publication of US4693966A publication Critical patent/US4693966A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00—Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20—Immunohistochemistry assay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal
    • Y10S530/865—Human

Definitions

  • This invention concerns hybridomas which produce human monoclonal antibodies recognizing surface antigens and intracellular components of human cells and a method for making such hybridomas.
  • the human monoclonal antibodies are useful in diagnosis of diseases associated with cancers.
  • Class 2 antigens are shared antigens, found on a proportion of allogeneic tumors as well as on autologous tumors; recent evidence indicates that some Class 2 antigens are autoantigenic differentiation antigens, as they are detected on a restricted range of normal tissues (Watanabe, T., C. S. Pukel, H. Takeyama, K. O. Lloyd, H. Shiku, L. T. C. Li, L. R. Travassos, H. F. Oettgen, and L. J. Old. 1982, J. Exp. Med. 156: 1884.).
  • Class 3 antigens are widely distributed on normal and malignant cultures; these broadly represented antigens have not been extensively analyzed. Whereas Class 3 reactivity is relatively common, antibodies to Class 1 and Class 2 antigens are found infrequently (10% of patients).
  • the present invention provides hybridomas producing human monoclonal antibodies and a method for forming such hybridomas.
  • the human monoclonal antibody producing hybridoma cell lines of the present invention were formed by fusing a human myeloma cell line, a mouse myeloma cell line or human lymphoblastoid cell line with human lymphocytes from normal individuals and from individuals having malignant melanoma.
  • the lymphocytes were obtained from lymph node or tumor specimen of normal individuals having malignant melanoma. Peripheral blood lymphocytes from normal individuals or individuals having malignant melanoma were also used in the fusions.
  • Human monoclonal antibodies produced by these hybridoma cell lines recognize cell surface antigens or cytoplamic components of human cells and are useful for differentiating between normal and malignant cells.
  • the present invention comprises human monoclonal antibodies produced by these hybridoma cell lines which produce human monoclonal antibodies which recognize cell surface antigens and cytoplasmic components.
  • the antigens recognized by these monoclonal antibodies are the Ma4 cell surface antigenic system and nucleii, nucleoli and cytoskeletal elements in the cytoplasm.
  • human monoclonal antibodies recognizing cell surface antigens and cytoplasmic components are antibodies Ma4, M307, M311, M304, M305 and M311. A panel comprised of these has been formed.
  • the present invention comprises in addition a method for distinguishing between normal and tumor human cells comprising immunoassay of the Ma4 antigenic system with the antibody Ma4. Melanoma, renal and breast tumors may be detected by the method.
  • the antibodies of the present invention are useful in the diagnosis of diseases associated with various cancers. Thus, these may be used to assay human epithelial cells by immunoassay of the Ma4 intracellular antigen with human monoclonal antibodies of the present invention.
  • the assay of the present invention comprises contacting a tissue containing melanoma cells with the antibody recognizing melanoma cell antigens, preferably monoclonal antibodies to one or more surface cell antigens or cytoplasmic components and observing the antigenic reaction between said monoclonal antibody and said antigen.
  • the tissue to be assayed is first excised and is then either freshly or after being frozen or embedded in paraffin by methods well-known in the art contacted with said monoclonal antibodies.
  • said antibodies may be tagged with colored groups or color forming substances such as enzymes, preferably peroxidase and its substrates, with flourescent substances or with radioactive elements by which the location of the antibodies may be traced.
  • Serological assay of excised tissue is also an embodiment of the present invention.
  • passive hemmaglutination, antibody inhibition assay, or glycolipid-mediated immune adherence assay may be used.
  • anti-mouse immunoglobulin assay and Protein A assays may be employed.
  • the tissue to be assayed comprises the intact body of an individual or a whole portion thereof, the antibody is administered to the individual, the antibody having been tagged with a radioactive or other energy-producing element, and the whole body or part thereof is scanned externally for localization of radioactivity at the site of tumor cells.
  • the method of the present invention also comprises treatment of tumors in a patient wherein the monoclonal antibody recognizing the cell antigen of melanoma cells, preferably the cell differentiation antigen, is administered to the patient in an amount effective to inhibit the growth or proliferation of tumor cells.
  • the antibody is tagged with a potentially tissue destructive agent which causes destructive agents comprise enemotoxic agents, chemotherapeutic agents, radionucleides, toxins, complement activators and clotting activators.
  • the cell lines disclosed in the present invention are deposition at the American Type Culture Collection, Bethesda, Md. and bear the following deposit numbers:
  • FIG. 1 depicts autoradiographs of [ 35 S] methionine-labeled immunoglobulins precipitated from culture supernatants of the Ma4 cell line (lane 1), LICR-2 human lymphoblastoid line (lane 2), Be3 cell line (lane 3) and SKO-007 human myeloma line (lane 4).
  • FIG. 2 shows reactivity of Ma4 culture supernatant with SK-RC-9 renal cancer cells as determined by three serological assays, i.e., Immunoadsorbence (IA), Protein A (PA), and Anti-IgA assays.
  • IA Immunoadsorbence
  • PA Protein A
  • Anti-IgA assays i.e., Anti-IgA assays.
  • FIG. 3 shows the reactivity via immunoadsorbence assay of Ma4 culture supernatants with four human cancer cell lines, i.e. SK-LC-13 (lung cancer), AlAb (breast cancer), SK-MEL-21 and SK-MEL-37 (melanomas).
  • FIG. 4 shows absorption analysis of IA reactivity of Ma4 culture supernatants (diluted 1:150) for SK-RC-9 renal cancer cells.
  • FIG. 5 shows intracellular antigens detected by IgM antibodies in supernatants of cultures derived from fusions of lymphocytes from lymph nodes of malenoma patients with LICR-2 (M304 and M305 antibodies) and SKO-007 (M307 and M311 antibodies).
  • A M311 detects a nuclear antigen (target SK-MEL-63 melanoma cell line), magnification 1000 ⁇ ;
  • B M307 detects a cytoskeletal structure (target cell WI-38 fetal fibroblasts), magnification 400 ⁇ ;
  • C M305 detects a dense cytoplasmic network (target cell WI-38), magnification 200 ⁇ ;
  • D M304 detects a cytoplasmic antigen expressed by cells of neuroectodermal origin (target cell SK-MEL-93 melanoma cell line), magnification 400 ⁇ .
  • FIG. 6 shows the reactivity of M304 antibody with a panel of cultured cells using indirect immunofluorescence assays. Horizontal bars indicate intensity (0 to 3+) of immunofluorescence reactions.
  • the human myeloma cell line SKO-007 (Olsson, L., and H. S. Kaplan. 1980, Proc. Nat'l. Acad. Sci., U.S.A. 77: 5429) was obtained from Becton-Dickinson Co., Sunnyvale, CA, and was rendered free of mycoplasma contamination by Dr. J. Fogh, Sloan-Kettering Institute. SKO-007 secretes ⁇ heavy chain and ⁇ light chain.
  • the human LICR LON/HMy2 (abbreviated LICR-2) cell line (Edwards, P. A. W., C. M. Smith, A. M. Neville, and M. J. O'Hare. 1982, Eur. J.
  • Immunol. 12: 641) was obtained from Drs. M. O'Hare, P. Edwards and M. Neville, London Branch of the Ludwig Institute for Cancer Research. This lymphoblastoid cell line secretes ⁇ 1 heavy chain and ⁇ light chain and expresses Epstein-Barr viris nuclear antigen (EBNA).
  • EBNA Epstein-Barr viris nuclear antigen
  • the human lymphoblastoid cell line GM 4672 developed from the GM 1500 cell line by Croce et al. (Croce, C. A., A. Linnenbach, W. Hall, Z. Steplewski, and H. Koprowski. 1980, Nature (Lond.) 288: 488, was obtained from the Human Genetic Mutant Cell Repository, Institute of Medical Research, Camden, NJ.
  • This cell line also expresses EBNA and secretes ⁇ 2 heavy chain and ⁇ light chain.
  • the mouse myeloma cell line NS-1 (Kohler, G., C. S. Howe, and C. Milstein. 1976, Eur. J. Immunol. 6: 292), was obtained from Dr. U. Hammerling, Sloan-Kettering Institute. These cell lines were grown in RPMI 1640 medium (containing 2 mM glutamine, 1% nonessential amino acids, 100 U/ml penicillin and 1 g/ml 8-azaguanine. No growth occurred in medium containing 4 ⁇ 10 -7 aminopterin.
  • Lymph node and tumor specimens from 33 patients with malignant melanoma were minced with fine scissors under sterile conditions. The resulting cell suspension was washed twice in RPMI 1640 medium and used as the source of lymphocytes for fusion.
  • Peripheral blood lymphocytes from 25 melanoma patients were purified from heparinized venous blood by Ficoll-Hypaque (Pharmacia Fine Chemicals, Division of Pharmacia, Inc., Piscataway, NJ) gradient centrifugation.
  • Ficoll-Hypaque Pulcoll-Hypaque
  • T lymphocytes were removed by rosetting with neuraminidase-treated sheep erythrocytes and centrifugation through a Ficoll-Hypaque gradient.
  • Lymphocytes and myeloma/lymphoblastoid cells were fused at ratios of 1:1 or 2:1 for 3 min at 37° C. in 0.2 ml 41.5% (w/v) polyethylene glycol [molecular weight 4000 (J. T. Baker Chemical Co., Phillipsburg, NJ)] dissolved in 15% (v/v) dimethyl sulfoxide. Between 2 ⁇ 10 6 and 5 ⁇ 10 7 lymphocytes were used in each fusion experiment. After fusion, cells were washed and left overnight in RPMI 1640 medium containing 15% FBS (v/v). Optimum FBS was between to to 20% (v/v).
  • the cells were then resuspended in RPMI 1640 medium containing 15% FBS, 2 ⁇ 10 -4 M hypoxanthine, 4 ⁇ 10 -7 M aminopterin, 3.2 ⁇ 10 -5 M thymidine and 2 ⁇ 10 -5 M 2-mercaptoethanol (HAT medium) and plated at 10 5 cells per well into Costar 3696 well plates (Costar, Cambridge, MA) preceeded with feeder layers prepared from BALB/c or C57BL/6 splenocytes (10 5 cells/well) or peritoneal cells (1-2 ⁇ 10 4 cells/well). Cells were maintained in HAT medium for a minimum of four week.
  • Ig production by cells derived from fusions with NS-1 and LICR-2 was examined by subculturing Ig + wells using a limiting dilution technique.
  • Cells from 77% (76/99) of Ig + wells from LICR-2 fusions continued to produce Ig after one subculture (between 2-3 months after fusion), and 61% remained Ig + after a second subculture (at 3-4 months).
  • a lower percentage of mouse/human clones had persistent Ig production; 58% (43/74) of Ig + wells from NS-1 fusions remained Ig + after the first subculture (at 2 months after fusion), and 30% were Ig + after the second subculture (at 3 months).
  • the line has been subcloned (1 cell/well) four times and has maintained stable production of IgM (5 ⁇ g/ml) and IgG (2 ⁇ g/ml) over a 12-month period.
  • the Ma4 cell line is tetraploid by flow cytometry and contains only human chromosomes by karyotypic analysis.
  • FIG. 1 shows that the Ma 4 line secretes two distinct sets of heavy and light chains.
  • Another Ig-secreting line derived from fusion of SKO-007 with lymphocytes from an axillary lymph node of a melanoma patient was cloned 2 times and has continued to produce IgG (without detectable reactivity) over a 5-month period.
  • SDS-PAGE analysis shows that this line, designated Be3, also produced two distinct sets of light and heavy chains (FIG. 1).
  • Supernatants from wells containing growing clusters of cells were assayed for human ⁇ , ⁇ or ⁇ heavy chains by an enzyme-linked immunoassay.
  • Costar 3696 96 well plates were precoated with human IgG (50 g/ml), IgA (50 g/ml), or igM (10 g/ml) (Cappel Laboratories, Cochranville, PA) overnight at 4° C.
  • the precoated wells were washed with phosphate-buffered saline pH 7.5 (PBS) and incubated with gammaglobulin-free FBS (Gibco Laboratories, Grand Island, NY) for 30 min.
  • PBS phosphate-buffered saline pH 7.5
  • gammaglobulin-free FBS Gibco Laboratories, Grand Island, NY
  • Goat anti-human ⁇ , ⁇ or ⁇ heavy chain antibodies linked to alkaline phosphatase (Sigma Chemical Co., St. Louis, MO), diluted 1:100, were mixed [1:1 (v/v)] with test supernatants or with IgG, IgA or IgM standards diluted in RPMI 1640 medium containing 15% FBS (final concentrations of standards were 10 ng/ml, 100 ng/ml, 1 ⁇ g/ml, 10 ⁇ g/ml and 100 ⁇ g/ml) and incubated for 90 min. The mixtures were then transferred to precoated wells, incubated for 60 min, and washed with PBS.
  • Alkaline phosphatase activity was detected using a p-nitrophenyldisodium phosphate substrate (Sigma Chemical Co.), with changes in optical density measured on an Artek Model 210 Reader (Artek Systems Corp., Farmingdale, NY).
  • the assay detected ⁇ 100 ng/ml of ⁇ , ⁇ or ⁇ heavy chains and was specific for each Ig class over a range of ⁇ 100 ng/ml to ⁇ 100 ⁇ g/ml.
  • Supernatants from wells containing ⁇ 200 ng/ml Ig were screened for reactivity to cellular antigens using the following panel of human tumor cell lines: Melanomas (SK-MEL-13,19,23,28,29,37,93,147,165 and MeWO); Malignant gliomas (U251Mg, SK-MG-3); Epithelial cancers (SK-RC-7, SK-RC-9, BT-20, CAMA, 253J, HT29, OV2774 and Calu-1).
  • target cells were plated in Falcon 3034 plates and red cell rosetting assays for IgG [protein A (PA) assay] and IgM [immune adherence (IA) assay] were performed as previously described (Shiku, H., T. Takahishi, H. F. Oettgen and L. H. Old. 1976, J. Exp. Med. 144: 873; Pfreundschuh, M., H. Shiku, T. Takahishi, R. Ueda, J. Ransohoff, H. F. Oettgen, and L. H. Old. 1978, Proc Natl. Acad. Sci., U.S.A. 75 5122).
  • PA protein A
  • IA immune adherence
  • IgA antibodies were detected by indicator cells prepared by conjugating purified anti-human IaA (Accurate Chemical and Scientific Corp., Westbury, NY) to human red blood cells with 0.01% chromium chloride. Absorption tests were performed according to previously described procedures (Carey, T. E., T. Takahaski, L. A. Resnick, H. F. Oettgen and L. J. Old. 1976, Proc. Nat'l. Acad. Sci., U.S.A. 73: 3278.). To detect intracellular antigens, supernatants were screened by indirect immunofluorescence tests. Target cells growing in Falcon 3034 plates were fixed with a 1:1 (v/v) methanol;acetone mixture for 5 min at room temperature.
  • the cells were incubated with supernatant for 1 hr at room temperature, washed, and incubated with a 1:50 dilution of goat anti-human Ig conjugated to FITC (Cappel Laboratories, Inc.) for 45 min. Fluorescence was evaluated with a Leitz Dialux 20 microscope.
  • Cells were cultured at 1 ⁇ 10 6 cells epr ml for 12 hrs in Eagle's minimum essential medium (lacking methionine), 1% FBS and 50 Ci[ 35 S] methionine (New England Nuclear, Boston, MA). Immunoglobulins in the culture fluid were precipitated with rabbit anti-human immunoglobulin antibodies (Accurate Chemical and Scientific Corp.) and S. aureus (Bethesda Research Laboratories, Bethesda, MD), and immunoprecipitates were analyzed by NaDodSo 4 /polyacrylamide gel electrophoresis (SDS-PAGE) according to Laemmli (Laemmli, U.K. 1970, Nature (Lond.) 227: 680).
  • FIG. 3 illustrates IA tests with Ma4 supernatant on 4 other established human cell lines; reactions were seen with SK-LC-13, a cell line derived from lung cancer, and AlAb, a cell line derived from breast cancer, but not with 2 melanoma cell lines.
  • FIG. 4 demonstrates analysis of Ma4 antibody reactivity by absorption analysis using a panel of 81 different cell types.
  • the antigen detected by Ma4 antibody was found to be heat stable (100° C. for 10 min) and resistant to treatment with trypsin and proteinase K. Chloroform:methanol extracts of the Ma4-positive cell line SK-RC-9 completely inhibited Ma4 antibody reactivity. Extracts from Ma4-negative cell lines (253J and BT-20) had no inhibitory activity.
  • Antibodies M305 and M307 reacted with cytoplasmic components in a wide range of cultured cell types; M307 stained a cytoskeletal network and staining with M305 showed a dense reticular pattern.
  • Antibody M304 also reacted with cytoplasmic components, but in the case of this antibody reactions were restricted to cell lines of neuroectodermal origin (FIG. 6). Astrocytomas (9 of 9 tested), melanomas (9 of 16 tested), neuroblastomas (1 of 3 tested) and normal melanocytes reacted with antibody M304. No reactions were observed with 18 epithelial cancers or with cultures of normal kidney or fibroblasts.
  • lymphocytes from regional lymph nodes, peripheral blood and tumor infiltrates, 157 lymphocytes were fused with any of SKO-007 (human myeloma line), LICR LON/HMy2 (LICR-2) and GM 4672 (human lymphoblastoid lines), or NS-1 (mouse myeloma line). Fusion of lymph node lymphocytes with NS-1 resulted in a 3 to 4 times higher frequency than fusion with SKO-007 or GM 4672.
  • fusion with NS-1 gave 25 times higher frequency of clones than fusion with LICR-2 or SKO-007.
  • Production of human ⁇ , ⁇ or ⁇ heavy chains was detected in 50-80% of wells containing growing clones, and the levels of immunoglobulin ranged from 0.3 ⁇ g-40 ⁇ g/ml.
  • NS-1 derived clones could be easily subcultured, while LICR-2 and SKO-007 clones grew more slowly on subculturing.
  • Ig-secretion appeared to be more stable property of LICR-2-derived clones than NS-1-derived clones.
  • a panel of 20 human cancer cell lines was used to screen 771 Ig-secreting cultures for antibody to cell surface or intracellular antigens. Reactivity with cell surface antigens was found infrequently (6 cultures), whereas reactivity with intracellular antigens was more common (27 cultures).
  • a new cell surface antigen with properties of a glycolipid was defined with an IgM monoclonal antibody secreted by a tetraploid cell derived from a fusion of LICR-2 with lymphocytes from the axillary lymph node of a patient with melanoma. The hybrid cell line has been subcloned 4 times and secretes 5 ⁇ g IgM/ml.
  • the antigen detected by this IgM antibody was found on 5/23 melanoma cell lines and 12/30 epithelial cancer cell lines. No ractions were found with 11 cultures derived from normal cells. Stable cell lines secreting human antibody detecting nuclei, nucleoli, cytoskeletal elements or other cytoplasmic components were also isolated in this study. One antibody detected an intracellular antigen that is restricted to cells of neuroectodermal derivation. Using these methods for isolating and analyzing human monoclonal antibody, it should now be possible to define the repertoire of the humoral immune response to melanoma.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Human monoclonal antibodies which specifically bind to antigens found on cell surfaces of renal, lung, and breast cancer cells, intracellular cytoskeletal antigens, nuclear antigens, and cytoplasmic reticular antigens are disclosed. The antibodies are the product of hybridoma cell lines, where the immortal cell line may be, e.g., a human cell line, or a murine cell line.

Description

BACKGROUND
This present invention was wholly or partially made with funds provided by the National Cancer Institute, Department of Human Health and Services under Grant No. CA-1766 and CA-08748. Accordingly, the United States Government has certain rights in this invention.
This invention concerns hybridomas which produce human monoclonal antibodies recognizing surface antigens and intracellular components of human cells and a method for making such hybridomas. The human monoclonal antibodies are useful in diagnosis of diseases associated with cancers.
Defining the antigenic changes that accompany malignant transformation and detecting whether these changes elicit immune recognition in the host of origin are central concerns of tumor immunology. Serological approaches to these issues have been vastly strengthened with the advent of hybridoma technology (Kohler, G. and C. Milstein. 1975, Nature (Lond.) 256: 495). Monoclonal antibodies are providing much new information about the antigenic structure of experimental and human cancers, and hybridoma analysis promises to be of great value in dissecting the humoral immune response to tumor antigens in tumor-bearing animals and humans.
The problem with past efforts to resolve the question of tumor-related immune response in humans using conventional serology has had to do with the issue of specificity (Old, L. J. 1981, Cancer Res. 41: 361). With the exception of virus-related antigens on tumors such as Burkitt's lymphoma and hepatoma (Giraldo, G. and E. Beth. 1980, The Role of Viruses in Human Cancer. Vol. 1 (Elsevier/North-Holland, New York)), and HLA antigens and blood group antigens, the nature and significance of other classes of human cancer antigens detected by human antibody are unknown. To assess the frequency and specificity of antibodies reacting with surface antigens of human cancer cells, we have analyzed the autologous reactivity of sera from a series of patients with melanoma. astrocytoma, renal cancer and leukemia (Carey, T. E., T. Takahishi, L. A. Resnick, H. F. Oettgen and L. H. Old. 1976, Proc. Natl. Acad. Sci., U.S.A. 73: 3278; Shiku, H., T. Takahishi, H. F. Oettgen and L. H. Old. 1976, J. Exp. Med. 144: 873; Shiku, H., T. Takahishi, L. A. Resnick, H. F. Oettgen and L. H. Old. 1977, J. Exp. Med. 145: 784; Albino, A. P., K. O. Lloyd, A. N. Houghton, H. F. Oettgen, and L. H. Old, 1981, J. Exp. Med. 154: 1764; Pfreundschuch, M., H. Shiku, T. Takahishi, R. Ueda, J. Ransohoff, H. F. Oettgen, and L. H. Old. 1978, Proc Natl. Acad. Sci., U.S.A. 75 5122; Ueda, R., H. Shiku, M. Pfreundschuh, T. Takahishi, W. Whitmore, Jr., H. F. Oettgen, K. O. Llyod, and L. J. Old. 1979, J. Exp. Med. 150: 564; Garrett, T. J., T. Takahishi, B. D. Clarkson, and L. J. Old. 1977, Proc. Natl Acad. Sci., U.S.A. 74: 4578). Three classes of antigens detected by autologous antibody have been defined in this way. Class 1 antigens are restricted to autologous tumor cells, not being detected on any other cell type, normal or malignant. Class 2 antigens are shared antigens, found on a proportion of allogeneic tumors as well as on autologous tumors; recent evidence indicates that some Class 2 antigens are autoantigenic differentiation antigens, as they are detected on a restricted range of normal tissues (Watanabe, T., C. S. Pukel, H. Takeyama, K. O. Lloyd, H. Shiku, L. T. C. Li, L. R. Travassos, H. F. Oettgen, and L. J. Old. 1982, J. Exp. Med. 156: 1884.). Class 3 antigens are widely distributed on normal and malignant cultures; these broadly represented antigens have not been extensively analyzed. Whereas Class 3 reactivity is relatively common, antibodies to Class 1 and Class 2 antigens are found infrequently (10% of patients).
Techniques for the production of human monoclonal antibodies using hybridoma methodology have been used to extend these studies of humoral immune reactions of cancer patients.
In contrast to the success of hybridoma technology in the production of mouse and rat monoclonal antibodies, comparable studies with human antibody-producing hybrids have lagged behind. The general experience of many investigators has been that fusion with drug-marked human myeloma or lymphoblastoid cell lines resulted in few clones with growth potential.
SUMMARY
The present invention provides hybridomas producing human monoclonal antibodies and a method for forming such hybridomas.
The human monoclonal antibody producing hybridoma cell lines of the present invention were formed by fusing a human myeloma cell line, a mouse myeloma cell line or human lymphoblastoid cell line with human lymphocytes from normal individuals and from individuals having malignant melanoma. The lymphocytes were obtained from lymph node or tumor specimen of normal individuals having malignant melanoma. Peripheral blood lymphocytes from normal individuals or individuals having malignant melanoma were also used in the fusions.
Human monoclonal antibodies produced by these hybridoma cell lines recognize cell surface antigens or cytoplamic components of human cells and are useful for differentiating between normal and malignant cells.
DESCRIPTION
The present invention comprises human monoclonal antibodies produced by these hybridoma cell lines which produce human monoclonal antibodies which recognize cell surface antigens and cytoplasmic components. Among the antigens recognized by these monoclonal antibodies are the Ma4 cell surface antigenic system and nucleii, nucleoli and cytoskeletal elements in the cytoplasm. More particularly, human monoclonal antibodies recognizing cell surface antigens and cytoplasmic components are antibodies Ma4, M307, M311, M304, M305 and M311. A panel comprised of these has been formed.
The present invention comprises in addition a method for distinguishing between normal and tumor human cells comprising immunoassay of the Ma4 antigenic system with the antibody Ma4. Melanoma, renal and breast tumors may be detected by the method.
The antibodies of the present invention are useful in the diagnosis of diseases associated with various cancers. Thus, these may be used to assay human epithelial cells by immunoassay of the Ma4 intracellular antigen with human monoclonal antibodies of the present invention.
The assay of the present invention comprises contacting a tissue containing melanoma cells with the antibody recognizing melanoma cell antigens, preferably monoclonal antibodies to one or more surface cell antigens or cytoplasmic components and observing the antigenic reaction between said monoclonal antibody and said antigen. In a preferred embodiment of the present invention the tissue to be assayed is first excised and is then either freshly or after being frozen or embedded in paraffin by methods well-known in the art contacted with said monoclonal antibodies. In this embodiment said antibodies may be tagged with colored groups or color forming substances such as enzymes, preferably peroxidase and its substrates, with flourescent substances or with radioactive elements by which the location of the antibodies may be traced. Serological assay of excised tissue is also an embodiment of the present invention. Thus passive hemmaglutination, antibody inhibition assay, or glycolipid-mediated immune adherence assay may be used. Likewise anti-mouse immunoglobulin assay and Protein A assays may be employed.
In another preferred embodiment of the present invention, the tissue to be assayed comprises the intact body of an individual or a whole portion thereof, the antibody is administered to the individual, the antibody having been tagged with a radioactive or other energy-producing element, and the whole body or part thereof is scanned externally for localization of radioactivity at the site of tumor cells.
The method of the present invention also comprises treatment of tumors in a patient wherein the monoclonal antibody recognizing the cell antigen of melanoma cells, preferably the cell differentiation antigen, is administered to the patient in an amount effective to inhibit the growth or proliferation of tumor cells. In a preferred embodiment of this method the antibody is tagged with a potentially tissue destructive agent which causes destructive agents comprise enemotoxic agents, chemotherapeutic agents, radionucleides, toxins, complement activators and clotting activators.
The following examples are intended to illustrate this invention without limiting same in any manner especially with respect to substantially functional equivalents of hybridomas, monoclonal antibodies and cell lines described and claimed herein.
AVAILABILITY OF HUMAN MONOCLONAL ANTIBODIES
The cell lines disclosed in the present invention are deposition at the American Type Culture Collection, Bethesda, Md. and bear the following deposit numbers:
______________________________________                                    
       HmAb  ATCC #                                                       
______________________________________                                    
       Ma4   8222                                                         
       M54   8234                                                         
       M304                                                               
       M305                                                               
       M307  8235                                                         
       M311  8236                                                         
______________________________________
Deposit is for the purpose of enabling disclosure only and is not intended to limit the concept of the present invention to the particular materials deposited.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 depicts autoradiographs of [35 S] methionine-labeled immunoglobulins precipitated from culture supernatants of the Ma4 cell line (lane 1), LICR-2 human lymphoblastoid line (lane 2), Be3 cell line (lane 3) and SKO-007 human myeloma line (lane 4).
FIG. 2 shows reactivity of Ma4 culture supernatant with SK-RC-9 renal cancer cells as determined by three serological assays, i.e., Immunoadsorbence (IA), Protein A (PA), and Anti-IgA assays.
FIG. 3 shows the reactivity via immunoadsorbence assay of Ma4 culture supernatants with four human cancer cell lines, i.e. SK-LC-13 (lung cancer), AlAb (breast cancer), SK-MEL-21 and SK-MEL-37 (melanomas).
FIG. 4 shows absorption analysis of IA reactivity of Ma4 culture supernatants (diluted 1:150) for SK-RC-9 renal cancer cells.
FIG. 5 shows intracellular antigens detected by IgM antibodies in supernatants of cultures derived from fusions of lymphocytes from lymph nodes of malenoma patients with LICR-2 (M304 and M305 antibodies) and SKO-007 (M307 and M311 antibodies). (A) M311 detects a nuclear antigen (target SK-MEL-63 melanoma cell line), magnification 1000×; (B) M307 detects a cytoskeletal structure (target cell WI-38 fetal fibroblasts), magnification 400×; (C) M305 detects a dense cytoplasmic network (target cell WI-38), magnification 200×; (D) M304 detects a cytoplasmic antigen expressed by cells of neuroectodermal origin (target cell SK-MEL-93 melanoma cell line), magnification 400×.
FIG. 6 shows the reactivity of M304 antibody with a panel of cultured cells using indirect immunofluorescence assays. Horizontal bars indicate intensity (0 to 3+) of immunofluorescence reactions.
PREPARATION OF HYBRIDOMAS Myeloma/Lymphoblastoid Cell Lines
The human myeloma cell line SKO-007 (Olsson, L., and H. S. Kaplan. 1980, Proc. Nat'l. Acad. Sci., U.S.A. 77: 5429) was obtained from Becton-Dickinson Co., Sunnyvale, CA, and was rendered free of mycoplasma contamination by Dr. J. Fogh, Sloan-Kettering Institute. SKO-007 secretes ε heavy chain and λ light chain. The human LICR LON/HMy2 (abbreviated LICR-2) cell line (Edwards, P. A. W., C. M. Smith, A. M. Neville, and M. J. O'Hare. 1982, Eur. J. Immunol. 12: 641) was obtained from Drs. M. O'Hare, P. Edwards and M. Neville, London Branch of the Ludwig Institute for Cancer Research. This lymphoblastoid cell line secretes γ1 heavy chain and κ light chain and expresses Epstein-Barr viris nuclear antigen (EBNA). The human lymphoblastoid cell line GM 4672, developed from the GM 1500 cell line by Croce et al. (Croce, C. A., A. Linnenbach, W. Hall, Z. Steplewski, and H. Koprowski. 1980, Nature (Lond.) 288: 488, was obtained from the Human Genetic Mutant Cell Repository, Institute of Medical Research, Camden, NJ. This cell line also expresses EBNA and secretes γ2 heavy chain and λ light chain. The mouse myeloma cell line NS-1 (Kohler, G., C. S. Howe, and C. Milstein. 1976, Eur. J. Immunol. 6: 292), was obtained from Dr. U. Hammerling, Sloan-Kettering Institute. These cell lines were grown in RPMI 1640 medium (containing 2 mM glutamine, 1% nonessential amino acids, 100 U/ml penicillin and 1 g/ml 8-azaguanine. No growth occurred in medium containing 4×10-7 aminopterin.
Fusion Procedure
Lymph node and tumor specimens from 33 patients with malignant melanoma were minced with fine scissors under sterile conditions. The resulting cell suspension was washed twice in RPMI 1640 medium and used as the source of lymphocytes for fusion. Peripheral blood lymphocytes from 25 melanoma patients were purified from heparinized venous blood by Ficoll-Hypaque (Pharmacia Fine Chemicals, Division of Pharmacia, Inc., Piscataway, NJ) gradient centrifugation. For further enrichment of B cells, T lymphocytes were removed by rosetting with neuraminidase-treated sheep erythrocytes and centrifugation through a Ficoll-Hypaque gradient.
Lymphocytes and myeloma/lymphoblastoid cells were fused at ratios of 1:1 or 2:1 for 3 min at 37° C. in 0.2 ml 41.5% (w/v) polyethylene glycol [molecular weight 4000 (J. T. Baker Chemical Co., Phillipsburg, NJ)] dissolved in 15% (v/v) dimethyl sulfoxide. Between 2×106 and 5×107 lymphocytes were used in each fusion experiment. After fusion, cells were washed and left overnight in RPMI 1640 medium containing 15% FBS (v/v). Optimum FBS was between to to 20% (v/v). The cells were then resuspended in RPMI 1640 medium containing 15% FBS, 2×10-4 M hypoxanthine, 4×10-7 M aminopterin, 3.2×10-5 M thymidine and 2×10-5 M 2-mercaptoethanol (HAT medium) and plated at 105 cells per well into Costar 3696 well plates (Costar, Cambridge, MA) preceeded with feeder layers prepared from BALB/c or C57BL/6 splenocytes (105 cells/well) or peritoneal cells (1-2×104 cells/well). Cells were maintained in HAT medium for a minimum of four week.
Cell Growth After Fusion of Lymphocytes with Myeloma/Lympho blastoid Cell Lines
Results of fusions with LICR-2, SKO-007, GM 4672 and NS-1 are presented in Table 1. Wells containing clonal outgrowth appeared most frequently after fusion with the NS-1 mouse myeloma line. Lymphocyte source did not influence the frequency of clonal outgrowth in the case of NS-1 fusions; clones appeared with equal frequency after fusion with lymphocytes from lymph node or peripheral blood. Fusions with the three human myeloma/lymphoblastoid cell lines resulted in a 3 to 25 times lower frequency of growing clones. In the case of lymphocytes from lymph node, fusion with LICR-2 resulted in a higher frequency of clonal outgrowth than fusion with SKO-007 or GM 4672. Uniformly poor results were obtained in LICR-2 or SKO-007 fusions with peripheral blood as the source of lymphocytes (median<1 clone per 107 lymphocytes fused). Enriching the B cell population of peripheral blood lymphocytes by depleting T cells prior to fusion with LICR-2, however, resulted in a higher frequency of growing clones. In three cases where a direct comparison of results with enriched B cells and unpurified peripheral blood lymphocytes was carried out, the frequency of clonal outgrowth was 5 to 20 times higher with the T cell-depleted population.
Immunoglobulin Production by Growing Clones
Supernatants from wells with growing cells were tested for human μ, γ or α heavy chain production. The LICR-2 line produced between 10 ng and 100 ng γ chain per ml supernatant, although an occasional well (<10%) contained as high as 2 μg γ chain/ml. GM 4672 produced 10 ng-1 μg/ml of IgG. Neither μ, γ or α heavy chains were detected in supernatants of SKO-007 or NS-1. After fusion, μ, γ (>200 ng/ml) or α heavy chains were found in 50-80% of wells (Table 1). The relative proportion of μ, γ or α-positive wells varied from specimen to specimen, and no consistent pattern was observed in relation to source of lymphocytes or the myeloma/lymphoblastoid line used as fusion partner (Table 1). The levels of Ig production ranged from 0.3 μg-40 μg/ml. Once again, no apparent relation was found between the level of Ig secreted and the different fusion partners or sources of lymphocytes. Wells containing more than one Ig class were often encountered after fusions with LICR-2 and SKO-007. In most cases, wells with two Ig classes contained heavy chain and a second heavy chain class, either μ or α. This could be due to the production of two heavy chains by the hybrid cells (in the case of LICR-2 or GM 4672 fusions), or to polyclonal outgrowth of Epstein-Barr virus (EBV)-transformed cells.
The stability of Ig production by cells derived from fusions with NS-1 and LICR-2 was examined by subculturing Ig+ wells using a limiting dilution technique. Cells from 77% (76/99) of Ig+ wells from LICR-2 fusions continued to produce Ig after one subculture (between 2-3 months after fusion), and 61% remained Ig+ after a second subculture (at 3-4 months). A lower percentage of mouse/human clones had persistent Ig production; 58% (43/74) of Ig+ wells from NS-1 fusions remained Ig+ after the first subculture (at 2 months after fusion), and 30% were Ig+ after the second subculture (at 3 months).
Screening of Immunoglobulin for Reactivity with Cell Surface Antigens
Supernatants of Ig+ wells were tested for reactivity with cell surface antigens by red cell rosetting assays using a panel of 20 cell lines, including 10 melanomas, 2 gliomas and 8 epithelial cancers (Table 2). Of 771 wells screened, positive reactions were observed with supernatants from 6 wells (0.8%). Efforts to isolate antibody secreting clones from these 6 wells resulted in the establishment of one cell line, designated Ma4, that continued to produce an IgM antibody to a surface antigen of human cells. The Ma4 line was derived from a fusion of LICR-2 with lymphocytes from a regional lymph node of a 35-year-old man with recurrent malignant melanoma. The line has been subcloned (1 cell/well) four times and has maintained stable production of IgM (5 μg/ml) and IgG (2 μg/ml) over a 12-month period. The Ma4 cell line is tetraploid by flow cytometry and contains only human chromosomes by karyotypic analysis. FIG. 1 shows that the Ma 4 line secretes two distinct sets of heavy and light chains. Another Ig-secreting line derived from fusion of SKO-007 with lymphocytes from an axillary lymph node of a melanoma patient was cloned 2 times and has continued to produce IgG (without detectable reactivity) over a 5-month period. SDS-PAGE analysis shows that this line, designated Be3, also produced two distinct sets of light and heavy chains (FIG. 1).
Immunoglobulin Assays
Supernatants from wells containing growing clusters of cells were assayed for human μ, γ or α heavy chains by an enzyme-linked immunoassay. Costar 3696 96 well plates were precoated with human IgG (50 g/ml), IgA (50 g/ml), or igM (10 g/ml) (Cappel Laboratories, Cochranville, PA) overnight at 4° C. The precoated wells were washed with phosphate-buffered saline pH 7.5 (PBS) and incubated with gammaglobulin-free FBS (Gibco Laboratories, Grand Island, NY) for 30 min. Goat anti-human μ, γ or α heavy chain antibodies linked to alkaline phosphatase (Sigma Chemical Co., St. Louis, MO), diluted 1:100, were mixed [1:1 (v/v)] with test supernatants or with IgG, IgA or IgM standards diluted in RPMI 1640 medium containing 15% FBS (final concentrations of standards were 10 ng/ml, 100 ng/ml, 1 μg/ml, 10 μg/ml and 100 μg/ml) and incubated for 90 min. The mixtures were then transferred to precoated wells, incubated for 60 min, and washed with PBS. Alkaline phosphatase activity was detected using a p-nitrophenyldisodium phosphate substrate (Sigma Chemical Co.), with changes in optical density measured on an Artek Model 210 Reader (Artek Systems Corp., Farmingdale, NY). The assay detected ≦100 ng/ml of μ, γ or α heavy chains and was specific for each Ig class over a range of ≦100 ng/ml to ≧100 μg/ml.
CHARACTERIZATION OF HUMAN MONOCLONAL ANTIBODIES FROM HYBRIDOMAS Antibody Reactivity to Cell Surface and Intracellular Antigens
Supernatants from wells containing ≧200 ng/ml Ig were screened for reactivity to cellular antigens using the following panel of human tumor cell lines: Melanomas (SK-MEL-13,19,23,28,29,37,93,147,165 and MeWO); Malignant gliomas (U251Mg, SK-MG-3); Epithelial cancers (SK-RC-7, SK-RC-9, BT-20, CAMA, 253J, HT29, OV2774 and Calu-1). To detect cell surface antigens, target cells were plated in Falcon 3034 plates and red cell rosetting assays for IgG [protein A (PA) assay] and IgM [immune adherence (IA) assay] were performed as previously described (Shiku, H., T. Takahishi, H. F. Oettgen and L. H. Old. 1976, J. Exp. Med. 144: 873; Pfreundschuh, M., H. Shiku, T. Takahishi, R. Ueda, J. Ransohoff, H. F. Oettgen, and L. H. Old. 1978, Proc Natl. Acad. Sci., U.S.A. 75 5122). IgA antibodies were detected by indicator cells prepared by conjugating purified anti-human IaA (Accurate Chemical and Scientific Corp., Westbury, NY) to human red blood cells with 0.01% chromium chloride. Absorption tests were performed according to previously described procedures (Carey, T. E., T. Takahaski, L. A. Resnick, H. F. Oettgen and L. J. Old. 1976, Proc. Nat'l. Acad. Sci., U.S.A. 73: 3278.). To detect intracellular antigens, supernatants were screened by indirect immunofluorescence tests. Target cells growing in Falcon 3034 plates were fixed with a 1:1 (v/v) methanol;acetone mixture for 5 min at room temperature. The cells were incubated with supernatant for 1 hr at room temperature, washed, and incubated with a 1:50 dilution of goat anti-human Ig conjugated to FITC (Cappel Laboratories, Inc.) for 45 min. Fluorescence was evaluated with a Leitz Dialux 20 microscope.
Chloroform:Methanol Extraction
Cells were extracted with chloroform:methanol by procedures described by Pukel, et al, J. Exp. Med 155: 1133 (1982). Antibody inhibition tests were carried out by mixing the cell extract with antibody containing supernatant (diluted two dilutions below the endpoint), incubating for 1 hr. at 20° C., and testing for residual antibody reactivity using SK-RC-9 target cells.
Radioimmunoprecipation Analysis of Secreted Immunoglobulins
Cells were cultured at 1×106 cells epr ml for 12 hrs in Eagle's minimum essential medium (lacking methionine), 1% FBS and 50 Ci[35 S] methionine (New England Nuclear, Boston, MA). Immunoglobulins in the culture fluid were precipitated with rabbit anti-human immunoglobulin antibodies (Accurate Chemical and Scientific Corp.) and S. aureus (Bethesda Research Laboratories, Bethesda, MD), and immunoprecipitates were analyzed by NaDodSo4 /polyacrylamide gel electrophoresis (SDS-PAGE) according to Laemmli (Laemmli, U.K. 1970, Nature (Lond.) 227: 680).
Definition of the Ma4 Antigen
Supernatants from cultures of the Ma4 cell line were found to be highly reactive with SK-RC-9 (an established cell line derived from human renal cancer) (FIG. 2). Reactivity was detected by IA assays for IgM antibody, but not by assays detecting IgA or IgG antibodies. [Serum from the patient providing lymphocytes used in the construction of the Ma4 cell line was unreactive (titer 1:2) with SK-RC-9 target cells by IA assay.] FIG. 3 illustrates IA tests with Ma4 supernatant on 4 other established human cell lines; reactions were seen with SK-LC-13, a cell line derived from lung cancer, and AlAb, a cell line derived from breast cancer, but not with 2 melanoma cell lines. FIG. 4 demonstrates analysis of Ma4 antibody reactivity by absorption analysis using a panel of 81 different cell types.
The antigen detected by Ma4 antibody was found to be heat stable (100° C. for 10 min) and resistant to treatment with trypsin and proteinase K. Chloroform:methanol extracts of the Ma4-positive cell line SK-RC-9 completely inhibited Ma4 antibody reactivity. Extracts from Ma4-negative cell lines (253J and BT-20) had no inhibitory activity.
Screening of Immunoglobulin for Reactivity to Intracellular Antigens
Supernatants from the 771 Ig+ wells that were tested for reactivity to cell surface antigens were also tested for reactivity to intracellular antigens by indirect immunofluorescence assays. Twenty-four (4%) wells contained antibodies reacting with nuclei, nucleoli, cytoskeletal elements or other cytoplasmic components (Table 2). Cell lines secreting IgM antibody were derived from 4 of these wells and antibody production by these lines has remained stable over a 4 to 7 months observation period. Antibodies M307 and M311 came from fusions of lymph node lymphocytes with SKO-007 and antibodies M304 and M305 from fusions of lymph node lymphocytes with LICR-2. Antibody M311 showed granular staining of the nucleus. Antibodies M305 and M307 reacted with cytoplasmic components in a wide range of cultured cell types; M307 stained a cytoskeletal network and staining with M305 showed a dense reticular pattern. Antibody M304 also reacted with cytoplasmic components, but in the case of this antibody reactions were restricted to cell lines of neuroectodermal origin (FIG. 6). Astrocytomas (9 of 9 tested), melanomas (9 of 16 tested), neuroblastomas (1 of 3 tested) and normal melanocytes reacted with antibody M304. No reactions were observed with 18 epithelial cancers or with cultures of normal kidney or fibroblasts.
In an attempt to analyze the humoral immune reactions of patients with malignant melanoma by hybridoma methodology, lymphocytes from regional lymph nodes, peripheral blood and tumor infiltrates, 157 lymphocytes were fused with any of SKO-007 (human myeloma line), LICR LON/HMy2 (LICR-2) and GM 4672 (human lymphoblastoid lines), or NS-1 (mouse myeloma line). Fusion of lymph node lymphocytes with NS-1 resulted in a 3 to 4 times higher frequency than fusion with SKO-007 or GM 4672. In the case of peripheral blood lymphocytes, fusion with NS-1 gave 25 times higher frequency of clones than fusion with LICR-2 or SKO-007. Production of human μ, γ or α heavy chains was detected in 50-80% of wells containing growing clones, and the levels of immunoglobulin ranged from 0.3 μg-40 μg/ml. NS-1 derived clones could be easily subcultured, while LICR-2 and SKO-007 clones grew more slowly on subculturing. In this study, Ig-secretion appeared to be more stable property of LICR-2-derived clones than NS-1-derived clones. A panel of 20 human cancer cell lines was used to screen 771 Ig-secreting cultures for antibody to cell surface or intracellular antigens. Reactivity with cell surface antigens was found infrequently (6 cultures), whereas reactivity with intracellular antigens was more common (27 cultures). A new cell surface antigen with properties of a glycolipid was defined with an IgM monoclonal antibody secreted by a tetraploid cell derived from a fusion of LICR-2 with lymphocytes from the axillary lymph node of a patient with melanoma. The hybrid cell line has been subcloned 4 times and secretes 5 μg IgM/ml. The antigen detected by this IgM antibody was found on 5/23 melanoma cell lines and 12/30 epithelial cancer cell lines. No ractions were found with 11 cultures derived from normal cells. Stable cell lines secreting human antibody detecting nuclei, nucleoli, cytoskeletal elements or other cytoplasmic components were also isolated in this study. One antibody detected an intracellular antigen that is restricted to cells of neuroectodermal derivation. Using these methods for isolating and analyzing human monoclonal antibody, it should now be possible to define the repertoire of the humoral immune response to melanoma.
                                  TABLE I                                 
__________________________________________________________________________
FUSION OF LYMPHOCYTES FROM MELANOMA PATIENTS WITH LICR-2, SK0-007, GM     
4672 OR NS-1                                                              
MYELOMA/LYMPHOBLASTOID CELL LINES                                         
                        NO. OF                                            
                 NO. OF WELLS WITH                                        
             NO. WELLS  CLONES PER 10.sup.7                               
                                           NO. (%) OF Ig.sup.+            
SOURCE OF    OF  WITH   LYMPHOCYTES        WELLS PRODUCING                
FUSION                                                                    
      LYMPHO-                                                             
             FU- GROWING                                                  
                        FUZED     NO. (%) OF                              
                                           Ig HEAVY CHAINS                
PARTNER                                                                   
      CYTES  SIONS                                                        
                 CLONES*                                                  
                        Median                                            
                             Range                                        
                                  Ig.sup.+                                
                                     WELLS.sup.+                          
                                           μ   γ                 
                                                         α          
__________________________________________________________________________
LICR-2                                                                    
      Lymph Node                                                          
             31  470    8.3  0-100                                        
                                  373                                     
                                     (79%) 189                            
                                              (51%)                       
                                                  280                     
                                                     (75%)                
                                                         72               
                                                           (19%)          
      Tumor   5  71     8.3  0-50 65 (91%) 37 (57%)                       
                                                  25 (38%)                
                                                         33               
                                                           (51%)          
      Infiltrate                                                          
      Peripheral                                                          
             31  45     <1.0 0-25 31 (69%) 7  (23%)                       
                                                  24 (77%)                
                                                         3 10%)           
      Blood                                                               
      Lymphocytes                                                         
      Peripheral                                                          
             10  12     6.1  0-25 9  (75%) 4  (33%)                       
                                                  7  (77%)                
                                                         0                
      Blood B Cells                                                       
SK0-007                                                                   
      Lymph Node                                                          
             22  50     1.0  0- 5 39 (78%) 19 (49%)                       
                                                  33 (85%)                
                                                         14               
                                                           (36%)          
      Tumor   2   1     --   0-1  0        --     --     --               
      Infiltrate                                                          
      Peripheral                                                          
             27  61     <1.0 0-33 52 (69%) 16 (31%)                       
                                                  38 (73%)                
                                                         12               
                                                           (23%)          
      Blood                                                               
      Lymphocytes                                                         
      Peripheral                                                          
              5  14     2.0  0-10 8  (57%) 4  (50%)                       
                                                  4  (50%)                
                                                         1 (13%)          
      Blood B Cell                                                        
GM 4672                                                                   
      Lymph Node                                                          
              8   8     1.0  0-1  8  (100%)                               
                                           2  (25%)                       
                                                  8  (100%)               
                                                         0                
NS-1  Lymph Node                                                          
             11  278    22.2 0-100                                        
                                  156                                     
                                     (56%) 68 (44%)                       
                                                  93 (60%)                
                                                         23               
                                                           (15%)          
      Peripheral                                                          
              6  66     25.0 0-50 30 (45%) 26 (87%)                       
                                                  10 (33%)                
                                                         5 (17%)          
      Blood Lymphocytes                                                   
__________________________________________________________________________
 *Wells with continuing outgrowth more than 2 weeks after fusion. Growing 
 clones derived from fusions with LICR2, SK0007 and GM 4672 appeared      
 between 3-8 weeks after fusion; growing clones from fusions with NS1     
 appeared between 2-6 weeks.                                              
 .sup.+Wells with clonal outgrowth containing >200 nq/ml μ, γ or 
 α heavy chain in the supernatant.                                  

                                  TABLE 2                                 
__________________________________________________________________________
SCREENING OF SUPERNATANTS FOR ANTIBODY REACTIVITY WITH CELL SURFACE       
ANTIGENS AND INTRACELLULAR ANTIGENS                                       
          MYELOMA/    NO. OF                  INTRACELLULAR ANTIGENS      
SOURCE OF LYMPHOBLASTOID                                                  
                      Ig.sup.+ WELLS                                      
                              CELL SURFACE ANTIGENS                       
                                              NU-  NU-    CYTO-           
LYMPHOCYTES                                                               
          CELL LINES  SCREENED*                                           
                              IA  PA  ANTI-IgA                            
                                              CLEAR                       
                                                   CLEOLAR                
                                                          PLASM           
__________________________________________________________________________
Lymph Node and                                                            
          LICR-2      438     2   1   0       2    1      8               
Tumor     GM 4672      8      0   0   0       0    0      0               
Infiltrates                                                               
          SK0-007     39      0   0   0       0    1      7               
          NS-1        156     1   1   0       0    0      6               
Peripheral Blood                                                          
          LICR-2      40      1   0   0       0    1      1               
          SK0-007     60      0   0   0       0    0      0               
          NS-1        30      0   0   0       0    0      0               
TOTAL:                771     4   2   0       2    3      22              
__________________________________________________________________________
 * Panel of cell lines tested: Melanomas                                  
 (SKMEL-13,19,23,28,29,37,93,147,165 and MeWo); Malignant gliomas (U251MG,
 SKMG-3); Epithelial Cancers (SKRC-7, SKRC-9, BT20, CAMA, 253J, HT29,     
 OV2774 and Calu1).                                                       

                                  TABLE 3                                 
__________________________________________________________________________
RESULTS OF DIRECT TESTS AND ABSORPTION ANALYSIS OF IA REACTIVITY OF Ma4   
CULTURE SUPERNATANT. DEFINITION OF THE Ma4 ANTIGEN SYSTEM                 
Cell Line     Titer*                                                      
                  Absorption                                              
                          Cell Line         Titer                         
                                               Absorption                 
__________________________________________________________________________
RENAL CANCER              MELANOMA                                        
SK-RC-4       -   -       SK-MEL-37 (BD)    -  -                          
SK-RC-7       -   -       SK-MEL-41 (BH)    -  -                          
SK-RC-9       1:1280                                                      
                  +       SK-MEL-90 (DO)    -  -                          
SK-RC-28      -   +       SK-MEL-93 (DX-1)  -  -                          
SK-RC-38      -   -       SK-MEL-93 (DX-2)  -  -                          
BLADDER CANCER            SK-MEL-110 (EI)   1:32                          
                                               +                          
T-24          1:64                                                        
                  +       SK-MEL-113 (EL)   -  -                          
639v          -   -       SK-MEL-118 (EQ)   -  -                          
Scb           -   +       SK-MEL-127 (EZ)   -  -                          
RT-4          -   -       SK-MEL-131 (FD)   -  -                          
253J          -   -       SK-MEL-147 (FT)   -  +                          
647v          -   -       SK-MEL-165 (GL)   -  -                          
TCC-SUP       -   -       MALIGNANT GLIOMA                                
BREAST CANCER             SK-MG-1           1:2                           
                                               +                          
ICF-7         -   -       SK-MG-3           -  -                          
CAMA          -   +       SK-MG-9           -  -                          
BT-20         -   -       SK-MG-10          -  -                          
AlAb          1:128                                                       
                  +       SK-MG-13          -  -                          
LUNG CANCER               J251 MG           -  -                          
Calu-1        -   -       J373 MG           1:15                          
                                               +                          
SK-LC-6       1:4 +       T98               -  -                          
SK-LC-8       -   -       HEMATOPOIETIC CELLS                             
SK-LC-13      1:4000                                                      
                  +       SK-LY-16             -                          
OVARIAN, CERVICAL         SK-LY-18                                        
AND UTERINE CANCER        EBV-TRANSFORMED B CELLS                         
ME-180        -   -       AH                   -                          
OV-2774       1:256                                                       
                  +       AV                   -                          
SK-OV-3       -   -       AZ                   -                          
Colo 316      -   -       DX                   -                          
ROAC          -   -       EI                   -                          
SK-UT-1       -   -       ADULT FIBROBLASTS                               
COLON CANCER              AS                                              
HT-29         -   +       BG                -                             
SW 620        -   -       DX                -  -                          
SW 480        1:2 +       RC-9              -  -                          
SW 1222       -   +       FETAL CELL LINES                                
MELANOMA                  WI-38             -  -                          
SK-MEL-13 (AH)                                                            
              -   -       F-5 Brain         -  -                          
SK-MEL-19 (AL)                                                            
              -   -       Flow 5000         -  -                          
SK-MEL-21 (AN)                                                            
              -   -       NORMAL KIDNEY                                   
SK-MEL-23 (AP)                                                            
              -   +       NK-1              -  -                          
SK-MEL-26 (AS)                                                            
              -   -       NK-2              -  -                          
MeWo          -   -       MELANOCYTES                                     
SK-MEL-28 (AU)                                                            
              -   -       FS 751            -                             
SK-MEL-29 (AV)                                                            
              -   +       FS 752            -                             
SK-MEL-30 (AW)                                                            
              -   -       RED BLOOD CELLS                                 
SK-MEL-31 (AX)                                                            
              -   -       A, B, AB, O                                     
SK-MEL-33 (AZ)                                                            
              1:128                                                       
                  +       Sheep erythrocytes                              
__________________________________________________________________________
 Footnotes to Table 3                                                     
 *Titer: (-) indicates no reaction in direct tests of undiluted culture   
 supernatants.                                                            
  Absorption: Culture supernatant (diluted 1:64 to 1:256 according to     
 endpoint) was absorbed with the indicated cell type and tested for       
 residual activity to SKRC-9 renal cancer target cells.

Claims (7)

What is claimed is:
1. Human monoclonal antibody Ma4 (HB8222), wherein said monoclonal antibody is IgM and specifically binds to an epitope of a glycolipid antigen, said antigen found on the cell surface of human renal, lung, and breast cancer cells.
2. Human monoclonal antibody M54 (HB 8234) which specifically binds to an antigen characteristic of human cells of epithelial origin.
3. Human monoclonal antibody M307 (HB 8235), wherein said monoclonal antibody is IgM and specifically binds to an intracellular cytoskeletal antigen of human cells.
4. Human monoclonal antibody M311 (HB 9054), wherein said monoclonal antibody specifically binds to a nuclear antigen of human cells.
5. A panel of human monoclonal antibodies, wherein said panel is used to characterize human cell antigens and said panel consists of at least one of the antibodies Ma4 (HB 8222), M54 (HB 8234), M307 (HB 8235) and M311 (HB 9054).
6. Hybridoma cell lines which produce monoclonal antibodies wherein said cell lines are selected from the group consisting of ATCC HB 8222, ATCC HB 8234, ATCC HB 8235, and ATCC HB 8236.
7. A method of characterizing human cell samples comprising contacting a sample of human cells with a panel of monoclonal antibodies which consists of at least two monoclonal antibodies selected from the group consisting of Ma4 (HB 8222), M54 (HB 8234), M307 (HB 8235) and M311 (HB 9054) under conditions favoring formation of complexes between said monoclonal antibodies and antigens of cells in said sample to which said monoclonal antibodies specifically bind, and determining the presence of said monoclonal antibody-antigen complexes.
US06/474,618 1983-03-11 1983-03-11 Human monoclonal antibodies from lymphocytes of patients with malignant melanoma Expired - Fee Related US4693966A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US06/474,618 US4693966A (en) 1983-03-11 1983-03-11 Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
EP84102522A EP0118893A3 (en) 1983-03-11 1984-03-08 Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
CA000449203A CA1242158A (en) 1983-03-11 1984-03-09 Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
JP59046964A JPS6012973A (en) 1983-03-11 1984-03-12 Single clone antibody of human from lymph of patient having malignant black tumor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/474,618 US4693966A (en) 1983-03-11 1983-03-11 Human monoclonal antibodies from lymphocytes of patients with malignant melanoma

Publications (1)

Publication Number Publication Date
US4693966A true US4693966A (en) 1987-09-15

Family

ID=23884319

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/474,618 Expired - Fee Related US4693966A (en) 1983-03-11 1983-03-11 Human monoclonal antibodies from lymphocytes of patients with malignant melanoma

Country Status (4)

Country Link
US (1) US4693966A (en)
EP (1) EP0118893A3 (en)
JP (1) JPS6012973A (en)
CA (1) CA1242158A (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
US4851510A (en) * 1984-11-30 1989-07-25 Wadley Technologies, Inc. Monoclonal antibodies to novel melanoma-associated antigens
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
WO1992018135A1 (en) * 1991-04-15 1992-10-29 The Regents Of The University Of California Compositions and methods for introducing effectors to pathogens and cells
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
US5242824A (en) * 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
US5286647A (en) * 1982-05-21 1994-02-15 University Of California Human-human hybridomas for neoplasms
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5612030A (en) * 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5882626A (en) * 1986-12-05 1999-03-16 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5935821A (en) * 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US6051387A (en) * 1982-05-21 2000-04-18 The Regents Of The University Of California Methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies
US20030152575A1 (en) * 1997-06-13 2003-08-14 Malaya Chatterjee Compositions and methods for treating tumors bearing HMFG and CEA antigens
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1254846A (en) * 1982-11-30 1989-05-30 Anthony Albino Monoclonal antibodies against melanocytes and melanomas
JPS61104783A (en) * 1985-09-10 1986-05-23 Wakunaga Seiyaku Kk Hybridoma producing anti-human carcinoma monoclonal antibody
JPS61104796A (en) * 1984-10-26 1986-05-23 Chemo Sero Therapeut Res Inst Preparation of monoclonal antibody
JPS61103837A (en) * 1984-10-26 1986-05-22 Wakunaga Seiyaku Kk Human anticancer monoclonal antibody
US4677070A (en) * 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
JPS6259531A (en) * 1985-09-06 1987-03-16 Ube Ind Ltd Production of barium ferrite powder
US4879225A (en) * 1986-06-20 1989-11-07 Neorx Corporation Enhanced production of antibodies utilizing insolubilized immune complexes
JPH0764567B2 (en) * 1986-12-27 1995-07-12 戸田工業株式会社 Plate-shaped magnetoplumbite type ferrite powder for magnetic recording
US5358660A (en) * 1988-01-14 1994-10-25 Showa Denko Kabushiki Kaisha Magnetic particles for perpendicular magnetic recording
DE3921211C1 (en) * 1989-06-28 1990-11-29 Idt Ag Fuer In Vivo Diagnostik Und Therapie, Zuerich, Ch
JPH07507923A (en) * 1992-03-20 1995-09-07 イムネット Human monoclonal antibodies and human monoclonal antibody production methods
EP4428159A1 (en) * 2023-03-10 2024-09-11 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Melanoma targeting human antibodies and therapeutic uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434230A (en) * 1981-08-12 1984-02-28 Research Corporation Human nonsecretory plasmacytoid cell line
US4444887A (en) * 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4451570A (en) * 1981-03-26 1984-05-29 The Regents Of The University Of California Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
US4472371A (en) * 1979-10-29 1984-09-18 Summa Medical Corporation Radiolabeled antibody to anti-tumor associated antigen and process

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57502090A (en) * 1980-07-18 1982-11-25
NZ198851A (en) * 1980-11-07 1984-07-31 Wistar Inst Stable,continuous human myeloma cell line capable of hybridisation with antibody-producing cells:production of hybrid cell line
US4594325A (en) * 1981-03-26 1986-06-10 The Regents Of The University Of Calif. High fusion frequency fusible lymphoblastoid cell line
JPS58201994A (en) * 1982-05-21 1983-11-25 Hideaki Hagiwara Method for producing antigen-specific human immunoglobulin
CA1254846A (en) * 1982-11-30 1989-05-30 Anthony Albino Monoclonal antibodies against melanocytes and melanomas

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472371A (en) * 1979-10-29 1984-09-18 Summa Medical Corporation Radiolabeled antibody to anti-tumor associated antigen and process
US4444887A (en) * 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4451570A (en) * 1981-03-26 1984-05-29 The Regents Of The University Of California Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
US4434230A (en) * 1981-08-12 1984-02-28 Research Corporation Human nonsecretory plasmacytoid cell line
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes

Non-Patent Citations (58)

* Cited by examiner, † Cited by third party
Title
Astaldi, G. C. B. et al, J. Immunology, vol. 128(6), pp. 2539 2542 (1982). *
Astaldi, G. C. B. et al, J. Immunology, vol. 128(6), pp. 2539-2542 (1982).
Cahan, L. D. et al, Proc. Natl. Acad. Sci., U.S.A., vol. 79 (pp. 7629 7633, (12 1982). *
Cahan, L. D. et al, Proc. Natl. Acad. Sci., U.S.A., vol. 79 (pp. 7629-7633, (12-1982).
Chiorazzi, N. et al, J. Exper. Med., vol. 156, pp. 930 935 (9 1982). *
Chiorazzi, N. et al, J. Exper. Med., vol. 156, pp. 930-935 (9-1982).
Croce, C. M. et al, Nature, vol. 288, pp. 488 489 (12 1980). *
Croce, C. M. et al, Nature, vol. 288, pp. 488-489 (12-1980).
Edwards, P. A. W. et al, Eur. J. Immunol., vol. 12, pp. 641 648 (8 1982). *
Edwards, P. A. W. et al, Eur. J. Immunol., vol. 12, pp. 641-648 (8-1982).
Glimcher, L. H. et al, Nature, vol. 298, pp. 283 184 (7 1982). *
Glimcher, L. H. et al, Nature, vol. 298, pp. 283-184 (7-1982).
Handley, H. H. et al. (1982) in Hybridomas in Cancer Diagnosis & Treatment, Mitchell, M. S. et al, eds. (Raven, N.Y.), pp. 125 132. *
Handley, H. H. et al. (1982) in Hybridomas in Cancer Diagnosis & Treatment, Mitchell, M. S. et al, eds. (Raven, N.Y.), pp. 125-132.
Human Lymphokines, Khan, A. et al, eds., Academic Press, N.Y. (1982), pp. 219 226, 343 350 and 699 718. *
Human Lymphokines, Khan, A. et al, eds., Academic Press, N.Y. (1982), pp. 219-226, 343-350 and 699-718.
Irie, R. F. et al, Br. J. Cancer, vol. 44, pp. 262 266 (1981), Chem. Abst. CA95(23): 201886d. *
Irie, R. F. et al, Br. J. Cancer, vol. 44, pp. 262-266 (1981), Chem. Abst. CA95(23): 201886d.
Irie, R. F. et al, Proc. Natl. Acad. Sci., U.S.A., vol. 79, pp. 5666 5670 (1982), Biol. Abst. 75027566. *
Irie, R. F. et al, Proc. Natl. Acad. Sci., U.S.A., vol. 79, pp. 5666-5670 (1982), Biol. Abst. 75027566.
Karpas, A. et al, Science, vol. 216, pp. 997 999 (5 1982). *
Karpas, A. et al, Science, vol. 216, pp. 997-999 (5-1982).
Koskimies, S., Scand. J. Immunology, vol. 11, pp. 73 77 (1980). *
Koskimies, S., Scand. J. Immunology, vol. 11, pp. 73-77 (1980).
Kozbor, D. et al, Proc. Natl. Acad. Sci., U.S.A., vol. 79, pp. 6651 6655 (11 1982). *
Kozbor, D. et al, Proc. Natl. Acad. Sci., U.S.A., vol. 79, pp. 6651-6655 (11-1982).
Lane, H. C. et al, J. Exp. Med., vol. 155, pp. 333 338 (1982). *
Lane, H. C. et al, J. Exp. Med., vol. 155, pp. 333-338 (1982).
Levy, R. et al, Proc. Natl. Acad. Sci., U.S.A., vol. 75(5), pp. 2411 2415 (5 1978). *
Levy, R. et al, Proc. Natl. Acad. Sci., U.S.A., vol. 75(5), pp. 2411-2415 (5-1978).
Marx, J. L., Science, vol. 229, pp. 455 456 (1985). *
Marx, J. L., Science, vol. 229, pp. 455-456 (1985).
Nilsson, K. et al, Clin. Exp. Immun., vol. 7, pp. 477ff, (1970). *
Nowinski, R. et al, Science, vol. 210, pp. 537 539 (1980). *
Nowinski, R. et al, Science, vol. 210, pp. 537-539 (1980).
O Hare, M. J. et al, Prot. Biol. Fluids, Coll. 30, pp. 265 268 (1982). *
O'Hare, M. J. et al, Prot. Biol. Fluids, Coll. 30, pp. 265-268 (1982).
Olsson, L. et al, Proc. Natl. Acad. Sci., U.S.A., vol. 77(9), pp. 5429 5431 (9 1980). *
Olsson, L. et al, Proc. Natl. Acad. Sci., U.S.A., vol. 77(9), pp. 5429-5431 (9-1980).
Pukel, C. S. et al, J. Exp. Med., vol. 155, p. 1133 (1982). *
Schlom, J. et al, Proc. Natl. Acad. Sci., U.S.A., vol. 77, pp. 6841 6845 (1980), Bio. Abst. 71053848. *
Schlom, J. et al, Proc. Natl. Acad. Sci., U.S.A., vol. 77, pp. 6841-6845 (1980), Bio. Abst. 71053848.
Schook, L. B. et al, Lymphokines, vol. 2, pp. 1 19, (1981), Academic Press, N.Y. *
Schook, L. B. et al, Lymphokines, vol. 2, pp. 1-19, (1981), Academic Press, N.Y.
Schwaber, J., Exp. Cell. Res., vol. 93, pp. 343 354 (1975). *
Schwaber, J., Exp. Cell. Res., vol. 93, pp. 343-354 (1975).
Sikora, K. et al, Blood, vol. 54(2), pp. 513 518 (8 1979). *
Sikora, K. et al, Blood, vol. 54(2), pp. 513-518 (8-1979).
Sikora, K. et al, Br. J. Cancer, vol. 43, pp. 105 107 (1981). *
Sikora, K. et al, Br. J. Cancer, vol. 43, pp. 105-107 (1981).
Sikora, K. et al, Nature, vol. 300, pp. 316 317 (11 1982). *
Sikora, K. et al, Nature, vol. 300, pp. 316-317 (11-1982).
Sikora, K. et al, The Lancet, 2, Jan. 2, 1982, pp. 11 14 (1 1982). *
Sikora, K. et al, The Lancet, 2, Jan. 2, 1982, pp. 11-14 (1-1982).
Steinitz, M. et al, Nature, vol. 269, pp. 420 422 (1977). *
Steinitz, M. et al, Nature, vol. 269, pp. 420-422 (1977).
Zurawski, V. R. et al, Clin. Res., vol. 26(3), p. 558A (1978). *
Zurawski, V. R. et al, Science, vol. 199, pp. 1439ff, (1978). *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286647A (en) * 1982-05-21 1994-02-15 University Of California Human-human hybridomas for neoplasms
US6051229A (en) * 1982-05-21 2000-04-18 The Regents Of The University Of California Human-human hybridom for neoplasms CLNH5 and CLNH11 specific antibody compositions
US6051693A (en) * 1982-05-21 2000-04-18 The Regents Of The University Of California CLNH11-specific antibodies
US6051387A (en) * 1982-05-21 2000-04-18 The Regents Of The University Of California Methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies
US4851510A (en) * 1984-11-30 1989-07-25 Wadley Technologies, Inc. Monoclonal antibodies to novel melanoma-associated antigens
US5654408A (en) * 1984-11-30 1997-08-05 Cytoclonal Pharmaceutics, Inc. Melanoma-associated antigens identified by monoclonal antibodies
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US6017514A (en) * 1986-12-05 2000-01-25 Techniclone Inc. Detection of necrotic malignant tissue and associated therapy
US6071491A (en) * 1986-12-05 2000-06-06 Techniclone, Inc. Detection of necrotic malignant tissue and associated therapy
US5882626A (en) * 1986-12-05 1999-03-16 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
US5242824A (en) * 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
WO1992018135A1 (en) * 1991-04-15 1992-10-29 The Regents Of The University Of California Compositions and methods for introducing effectors to pathogens and cells
US5212075A (en) * 1991-04-15 1993-05-18 The Regents Of The University Of California Compositions and methods for introducing effectors to pathogens and cells
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US5935821A (en) * 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5612030A (en) * 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US6509016B1 (en) 1995-01-17 2003-01-21 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US20030114398A1 (en) * 1995-01-17 2003-06-19 Malaya Chatterjee Monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US20050287148A1 (en) * 1995-01-17 2005-12-29 Malaya Chatterjee Monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US7517967B2 (en) 1995-01-17 2009-04-14 University Of Kentucky Research Foundation Monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US20060018895A1 (en) * 1995-01-29 2006-01-26 Malaya Chatterjee Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US7083943B1 (en) 1995-01-29 2006-08-01 Malaya Chatterjee Polynucleotides related to murine anti-idiotype antibody 11D10 and methods of use thereof
US7399849B2 (en) 1995-01-29 2008-07-15 University Of Kentucky Research Foundation Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US20030152575A1 (en) * 1997-06-13 2003-08-14 Malaya Chatterjee Compositions and methods for treating tumors bearing HMFG and CEA antigens

Also Published As

Publication number Publication date
CA1242158A (en) 1988-09-20
JPS6012973A (en) 1985-01-23
EP0118893A2 (en) 1984-09-19
EP0118893A3 (en) 1988-01-13

Similar Documents

Publication Publication Date Title
US4693966A (en) Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
Houghton et al. Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma.
Cote et al. Generation of human monoclonal antibodies reactive with cellular antigens.
US4613576A (en) Human monoclonal antibodies to cancer cells
Epstein et al. Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors.
EP0109441B1 (en) Human-human hybridomas for neoplasms
Ueda et al. Cell surface antigens of human renal cancer defined by mouse monoclonal antibodies: identification of tissue-specific kidney glycoproteins.
US4451570A (en) Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
MEEKER et al. A unique human B lymphocyte antigen defined by a monoclonal antibody
US4727021A (en) Human monoclonal antibodies to cytokeratin
US4695538A (en) Human monoclonal antibodies to cell surface antigens
JP3158119B2 (en) Monoclonal antibodies specific for a novel epitope of LFA-1 antigen on human T lymphocytes
EP0160250A2 (en) Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma
US4626507A (en) Hybridomas producing monoclonal antibodies specific for a human cell surface glycoprotein
Yoshino et al. Identification of antigenically distinct hemocyte subpopulations in Biomphalaria glabrata (Gastropoda) using monoclonal antibodies to surface membrane markers
Olsson et al. Antibody producing human-human hybridomas. II. Derivation and characterization of an antibody specific for human leukemia cells.
Wang et al. Preparation and characterization of monoclonal antibodies recognizing three distinct differentiation antigens (BL1, BL2, BL3) on human B lymphocytes.
US4752582A (en) Monoclonal antibodies to human glycophorin A and cell lines for the production thereof
US5081230A (en) Monoclonal antibodies reactive with normal and oncogenic forms of the ras p21 protein
US5024946A (en) Human monoclonal antibody to antigen of gastric cancer and B-cell line for producing this antibody, method for preparing this B-cell line and antibody, antigen and method of preparation of this antigen
WO1986005188A1 (en) Monoclonal antibodies and assay
CA1221648A (en) Monoclonal antibodies to human renal cancer antigens and method
US6051387A (en) Methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies
JP2555028B2 (en) Monoclonal antibody for human non-small cell lung cancer
Sinkovics et al. Monoclonal antibodies of hybridomas

Legal Events

Date Code Title Description
AS Assignment

Owner name: SLOAN-KETTERING INSTITUTE, 1275 YORK AVE., NEW YOR

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:HOUGHTON, ALAN N.;BROOKS, HANNAH;COTE, RICHARD J.;AND OTHERS;REEL/FRAME:004107/0112

Effective date: 19830310

AS Assignment

Owner name: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, 127

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:SLOAN-KETTING INSTITUTE;REEL/FRAME:004288/0150

Effective date: 19840731

Owner name: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH,NEW

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SLOAN-KETTING INSTITUTE;REEL/FRAME:004288/0150

Effective date: 19840731

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 19950920

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362